之江生物
(688317)
| 流通市值：31.31亿 | | | 总市值：31.31亿 |
| 流通股本：1.95亿 | | | 总股本：1.95亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 51,227,345.41 | 274,333,302.55 | 205,201,872.85 | 146,918,051.33 |
| 营业收入 | 51,227,345.41 | 274,333,302.55 | 205,201,872.85 | 146,918,051.33 |
| 二、营业总成本 | 17,171,479.82 | 262,813,916.58 | 166,756,990.8 | 110,791,802.06 |
| 营业成本 | 12,461,980.48 | 95,680,295.79 | 77,167,741.89 | 61,363,004.65 |
| 税金及附加 | 1,776,765.36 | 6,196,747.9 | 3,978,676.42 | 2,408,847.72 |
| 销售费用 | 17,470,695.11 | 95,208,091.21 | 69,221,637.21 | 49,313,089.83 |
| 管理费用 | 18,697,810.27 | 89,509,965.88 | 60,984,243.35 | 38,699,501.85 |
| 研发费用 | 12,145,804.86 | 61,003,822.15 | 42,353,979.69 | 28,269,502.3 |
| 财务费用 | -45,381,576.26 | -84,785,006.35 | -86,949,287.76 | -69,262,144.29 |
| 其中:利息费用 | 70,705.45 | 351,598.51 | 251,513.12 | 176,260.41 |
| 其中:利息收入 | 44,271,028.69 | 67,541,068.09 | 56,977,904.73 | 32,496,898.49 |
| 资产处置收益 | 39,305.59 | - | - | - |
| 资产减值损失(新) | -3,486,897.84 | -186,453,781.91 | -4,328,195.61 | -5,003,404.26 |
| 信用减值损失(新) | -420,869.85 | -2,359,686.44 | 1,425,400.16 | 578,672.61 |
| 其他收益 | 1,217,737.8 | 27,795,326.24 | 17,096,673.5 | 15,392,979.75 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 31,405,141.29 | -149,498,756.14 | 52,638,760.1 | 47,094,497.37 |
| 加:营业外收入 | 25,056.37 | 1,079,368.21 | 343,928.61 | 254,064.59 |
| 减:营业外支出 | 150.35 | 8,213,469.58 | 6,565,845.68 | 6,496,680.53 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 31,430,047.31 | -156,632,857.51 | 46,416,843.03 | 40,851,881.43 |
| 减:所得税费用 | 4,523,132.97 | -19,775,784.17 | 11,775,536.22 | 9,232,281.18 |
| 六、净利润 | 26,906,914.34 | -136,857,073.34 | 34,641,306.81 | 31,619,600.25 |
| 持续经营净利润 | 26,906,914.34 | -136,857,073.34 | 34,641,306.81 | 31,619,600.25 |
| 归属于母公司股东的净利润 | 26,906,914.34 | -136,857,073.34 | 34,641,306.81 | 31,619,600.25 |
| (一)基本每股收益 | 0.14 | -0.71 | 0.18 | 0.17 |
| (二)稀释每股收益 | 0.14 | -0.71 | 0.18 | 0.17 |
| 八、其他综合收益 | -5,158,595.36 | -7,874,922.49 | -9,505,020.43 | 727,403.45 |
| 归属于母公司股东的其他综合收益 | -5,158,595.36 | -7,874,922.49 | -9,505,020.43 | 727,403.45 |
| 九、综合收益总额 | 21,748,318.98 | -144,731,995.83 | 25,136,286.38 | 32,347,003.71 |
| 归属于母公司股东的综合收益总额 | 21,748,318.98 | -144,731,995.83 | 25,136,286.38 | 32,347,003.71 |
| 公告日期 | 2024-04-29 | 2024-04-22 | 2023-10-27 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |